Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

37
Closing Bell: Sensex up 257 pts, Nifty ends above 10,800 but market breadth in favour of bears

2018-06-22 moneycontrol
Market Update: European markets were trading higher amid uncertainty over whether OPEC would manage to increase crude output at a meeting in Vienna later in the day. Britain's FTSE and France's CAC were up 0.7 percent at the time of writing this article.
500325 HCTHY 535789 534816 500135 532281 500378 BJJQY RLNIY AXB UNITDSPR ESSELPRO JETAIRWAYS CANFINHOME 511196 531213 532432 AXBA BAJFINANCE FORTIS JINDALSAW HCLTECH 500180 UQNTY BHRYY 539254 RELIANCE IDBI 532617 531768 533155 BHRQY JUBLFOOD 532215 AXISBANK RIGD JBLWY MANAPPURAM INFRATEL HDFCBANK BHARTIARTL 500034 ADANITRANS INDIGO 500116 IBN IDKQY 532843 539448 AXBKY IBULHSGFIN 532454 ICICIBANK HDB 532174 POLYMED

31
Market Live: Sensex sees a sharp surge, Nifty hits 10,800; banks, pharma soar

2018-06-22 moneycontrol
Market Check: Equity benchmarks are trading at the high points of the day, with the Nifty hitting 10,800-mark now. The Sensex is up over 100 points. Strong gains in financials, namely PSU banks, is aiding sentiment on D-Street. Sharp upmoves are visible in sectors such as pharma, FMCG, energy and infra names. Midcaps too have added to their gains, trading around quarter of a percent higher. Sun Pharma is leading the gainers chart on Sensex and Nifty, followed by Bajaj Finance and M&M, while Reliance, Wipro, and HPCL have lost the most.
BHRYY 500325 500228 RELIANCE IDBI HCTHY 512573 532714 531768 500470 GRANULES 532482 534816 RIGD 500135 532281 HDFCBANK 500378 BJJQY INFRATEL KEC RLNIY 500034 500116 AVANTI IBN ESSELPRO JSWSTEEL ICICIBANK BAJFINANCE TTST TATASTEEL TATLY HDB 532174 500180 JINDALSAW HCLTECH 534809 PCJEWELLER POLYMED

31
Market Live: Rangebound trade continues ahead of OPEC decision; ITC, HDFC support

2018-06-22 moneycontrol
Jindal Saw in focus: Pipe manufacturer Jindal Saw said it is currently not exporting large diameter pipes to the United States and the countervailing duty imposed by the US won't have any impact on company's business.
BHRYY 500325 500228 RELIANCE IDBI 533273 HCTHY 512573 532714 500470 GRANULES 532482 534816 RIGD 500135 532281 HDFCBANK 500378 BJJQY INFRATEL KEC RLNIY 500034 500116 AVANTI IBN ESSELPRO JSWSTEEL ICICIBANK OBZIY BAJFINANCE TTST OBEROIRLTY TATASTEEL TATLY HDB 532174 500180 JINDALSAW HCLTECH 534809 PCJEWELLER

0
Jindal Saw Limited - Updates

2018-06-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
JINDALSAW 500378

0
AstraZeneca gets nod to launch cancer drug

2018-06-21 thehindubusinessline
AstraZeneca Pharma India on Friday said that it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine. The nod paves the way for it to launch the product in the country. Durvalumab is indicated as a treatment option for patients with locally-advanced, unresectable non-small cell lung cancer and metastatic urothelial carcinoma. Shareholders will closely monitor the development.
JINDALSAW 500378 ASTRAZEN 506820

0
Broker's call: Capacite Infra

2018-06-21 thehindubusinessline
Capacite Infraprojects’ huge order book of ₹5,682 crore (4.2x of FY18 revenue) with an average project timeline of 3-3.5 years offers revenue growth of 21.8 per cent in FY19 and 19.5 per cent in FY20 respectively.
JINDALSAW 500378

0
Company news: Atishay

2018-06-21 thehindubusinessline
Atishay has won the project for providing technical support services for Rajasthan UID (Aadhaar) through open competitive bidding (e-tender). The total price consideration for the project is about ₹1.40 crore, it said in a disclosure to the BSE. The company has to deploy technical resources at the client site (Department of Information Technology Communication, Jaipur). The deployed resources will provide proactive assistance to the concerned officials for successful implementation of UID technical projects in Rajasthan.
JINDALSAW 500378

0
Will WHO grant boost Strides Shasun?

2018-06-21 thehindubusinessline
Strides Shasun on Friday announced the receipt of prequalification from the World Health Organisation for its 100-mg rectal artesunate suppositories for pre-referral management of severe malaria. Achieved with support from MMV and funding from Unitaid, this prequalification enables countries to procure life-saving RAS with donor funding, thus ensuring increased access to this potentially life-saving intervention, Strides Shasun said.
JINDALSAW 500378

0
Focus on DIL merger with its subsidiary

2018-06-21 thehindubusinessline
The board of DIL on Thursday approved a scheme of amalgamation with its subsidiary Fermenta Biotech, a manufacturer/marketer of bulk drugs including Vitamin D3 and enzymes. Under the terms, 100 equity shares of DIL of ₹10 each would be issued for every 1,006 equity shares of FBL. As the board on June 18 recommended a stock split (to ₹5) and 1:1 bonus, FBL shareholders would receive 100 DIL shares for every 251 shares held in FBL.
JINDALSAW 500378

74
Dollar scales 11-month peak, oil slides ahead of OPEC meet

2018-06-21 thehindubusinessline
The dollar powered to an 11-month high in the currency market, maintaining pressure on inflation and on countries and firms that have gorged themselves on dollar-denominated debt in recent years.
FOX CCV.CL CCV CMCSA JINDALSAW CCZ 500378 FOXA CMCSK DIS

21
Market Live: Nifty struggles below 10,800; Jhunjhunwala says 2018 is the year of consolidation

2018-06-21 moneycontrol
KNR in focus: In a clarification note to the exchanges regarding "Promoters of Company taking large interest free loan from the Company", KNR Constructions said the promoters have extended unsecured loan of Rs 214.08 crore to the company, at the interest rate of 8.45 percent per annum to defray the term loan of one of the SPV. "There are no loans and advances given by the Company to promoters."
OPTOCIRCUI 500325 RELIANCE IDBI 539254 533155 JUBLFOOD 511288 CMQMY RIGD JBLWY CUMMINSIND HDFCBANK 500378 RLNIY SBAZ ADANITRANS GRUH INDIGO 500116 534690 IBN GRHFY 532942 539207 539448 KNRCON 500480 ICICIBANK LAKSHVILAS HDB 532174 500180 JINDALSAW 532391 MANPASAND

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...